Category

Press Releases
03
May

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

3 May 2022
Read More
27
Apr

Coave Therapeutics will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado 1-4 May 2022. The meeting will also be available for virtual attendees 11-12 May.

27 April 2022
Read More
13
Apr

Coave Therapeutics to Present at Cell & Gene Meeting on the Mediterranean

13 April 2022
Read More
15
Nov

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

15 November 2021
Read More
12
Oct

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

12 October 2021
Read More
16
Sep

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

16 September 2021
Read More
21
Jul

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

21 July 2021
Read More
WordPress Cookie Plugin by Real Cookie Banner